Drug Profile
Protein tyrosine tyrosine - Novo nordisk
Alternative Names: NN 9748; NN9747; PYY-1562Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Peptide hormones
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Obesity in Denmark
- 28 Apr 2022 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Denmark
- 20 Jun 2019 Protein tyrosine tyrosine is still in phase I clinical trials in Type 2 diabetes mellitus and Obesity in Denmark (Novo Nordisk pipeline, June 2019)